Targeted endometrial cancer therapy as a future prospect

Women's Health

Volumn 9, Issue 2, 2013, Pages 189-199

  Thanapprapasr, Duangmani ^a   Cheewakriangkrai, Chalong ^b   Likittanasombut, Puchong ^a   Thanapprapasr, Kamolrat ^c   Mutch, David G ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c NATIONAL METAL AND MATERIALS TECHNOLOGY CENTER   (Thailand)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

endometrial cancer; targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

AGING; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERY RUPTURE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BREAST CANCER; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FATIGUE; FEMALE; GENE; HAND FOOT SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYSTERECTOMY; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MENOPAUSE; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; OBESITY; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PNEUMONIA; PROGRESSION FREE SURVIVAL; PTEN GENE; RASH; RECURRENCE RISK; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; THROMBOSIS; UTERUS SURGERY;

AGING; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; HUMANS; OBESITY; POSTMENOPAUSE; TAMOXIFEN; UNITED STATES;

EID: 84874892992     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.4     Document Type: Review

References (106)

1. Sivridis E, Giatromanolaki A. The pathogenesis of endometrial carcinomas at menopause: facts and figures. J. Clin. Pathol. 64(7), 553-560 (2011).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94(2), 153-156 (2001).
3. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356(9233), 881-887 (2000).
4. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation -implications for a novel treatment strategy. Gynecol. Oncol. 116(1), 92-98 (2010).
5. Hanna RK, Zhou C, Malloy KM et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol. Oncol. 125(2), 458-469 (2012).
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
7. American Cancer Society. Cancer Facts & Figures 2012. American Cancer Society, Atlanta, GA, USA (2012).
8. Thanapprapasr D, Wilailak S. Epidemiology of cancer and cancer control in Thailand. In: Cancer Report 2010 (1st Edition). Tuncer AM (Ed.). Medical & Nobel Publishing, Ankara, MN, USA, 410-413 (2010).
9. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
10. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J. Clin. Oncol. 27(8), 1214-1219 (2009).
11. Richter CE, Qian B, Martel M et al. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecol. Oncol. 114(1), 99-104 (2009).
12. Zivanovic O, Carter J, Kauff ND, Barakat RR. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol. Oncol. 115(3), 504-509 (2009).
13. Poilblanc M, Samouelian V, Querleu D. [Ovarian preservation during treatment of early stage endometrial cancer]. Bull. Cancer 99(1), 61-68 (2012).
14. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355(9213), 1404-1411 (2000).
15. Keys HM, Roberts JA, Brunetto VL et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92(3), 744-751 (2004).
16. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst. Rev. (10), CD003175 (2011).
17. Randall ME, Filiaci VL, Muss H et al. Randomized Phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 24(1), 36-44 (2006).
18. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1), S105-S143 (2006).
19. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J, Clin. Oncol. 25(20), 2983-2990 (2007).
20. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 366(9484), 491-505 (2005).
21. Zagouri F, Bozas G, Kafantari E et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet. Gynecol. Int. 2010, 749579 (2010).
22. Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr. Opin. Oncol. 24(5), 554-63. (2012).
23. Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front. Biosci. (Schol. Ed.) 3, 82-97 (2011).
24. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for antiangiogenesis strategies in gynecologic cancer. Curr. Pharm. Des. 18(19), 2713-2719 (2012).
25. Shahzad MM, Mangala LS, Han HD et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4), 309-319 (2011).
26. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15(1), 10-17 (1983).
27. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65(23), 10669-10673 (2005).
28. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18(16), 1926-1945 (2004).
29. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 33(4), 407-420 (2006).
30. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin. Investig. Drugs 19(8), 919-930 (2010).
31. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin. Cancer Res. 18(21), 5856-5864 (2012).
32. Dancey JE. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16(5), 1101-1114 (2002).
33. Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J. Clin. Oncol. 29(24), 3278-3285 (2011).
34. Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat. Rev. 38(6), 767-775 (2012).
35. Slomovitz BM, Lu KH, Johnston T et al. A Phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23), 5415-5419 (2010).
36. Shoji K, Oda K, Kashiyama T et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PloS ONE 7(5), e37431 (2012).
37. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82(1), 4-6 (1990).
38. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133(2), 275-288 (1971).
39. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
40. Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res. 21(6B), 4383-4388 (2001).
41. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671-680 (2005).
42. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev. Anticancer Ther. 7(4), 433-445 (2007).
43. Aghajanian C, Sill MW, Darcy KM et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 29(16), 2259-2265 (2011).
44. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 27(5B), 3525-3528 (2007).
45. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 12(12), 1109-1117 (2011).
46. Coleman RL, Sill MW, Lankes HA et al. A Phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 127(3), 538-543 (2012).
47. Dutt A, Salvesen HB, Chen TH et al. Drugsensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA 105(25), 8713-8717 (2008).
48. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int. J. Oncol. 33(2), 233-237 (2008).
49. Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Fut. Oncol. 5(1), 27-32 (2009).
50. Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int. J. Gynecol. Cancer 22(9), 1517-1526 (2012).
51. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 19(2), 124-134 (2007).
52. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 65(10), 1566-1584 (2008).
53. Santin AD, Bellone S, Van Stedum S et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol. Oncol. 98(1), 24-30 (2005).
54. Slomovitz BM, Broaddus RR, Burke TW et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 22(15), 3126-3132 (2004).
55. Morrison C, Zanagnolo V, Ramirez N et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J. Clin. Oncol. 24(15), 2376-2385 (2006).
56. Fleming GF, Sill MW, Darcy KM et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 116(1), 15-20 (2010).
57. Santin AD. Letter to the Editor referring to the manuscript entitled: 'Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study' recently reported by Fleming et al., (Gynecol. Oncol. 116, 15-20 [2010]).
58. Gynecol. Oncol. 118(1), 95-96; author reply 96-97 (2010).
59. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet. 102(2), 128-131 (2008).
60. Jewell E, Secord AA, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int. J. Gynecol. Cancer 16(3), 1370-1373 (2006).
61. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer 16(5), 1897-1902 (2006).
62. Elsahwi KS, Santin AD. erbB2 overexpression in uterine serous cancer: a molecular target for trastuzumab therapy. Obstet. Gynecol. Int. 2011, 128295 (2011).
63. Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 108(1), 3-9 (2008).
64. Oza AM, Eisenhauer EA, Elit L et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J. Clin. Oncol. 26(26), 4319-4325 (2008).
65. Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59(Suppl. 2), 21-26 (2004).
66. Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, Leslie KK. EGFR isoforms and gene regulation in human endometrial cancer cells. Mol. Cancer 9, 166 (2010).
67. Konecny GE, Venkatesan N, Yang G et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer 98(6), 1076-1084 (2008).
68. Leslie KK, Sill MW, Lankes HA et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group Phase II trial of persistent or recurrent endometrial cancer. Gynecol. Oncol. 127(2), 345-350 (2012).
69. Slomovitz BM, Broaddus RR, Schmandt R et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol. Oncol. 95(1), 32-36 (2004).
70. Nimeiri HS, Oza AM, Morgan RJ et al. A Phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 117(1), 37-40 (2010).
71. Bottsford-Miller JN, Sanguino AM, Thanapprapasr D et al. Enhancing antiangiogenic therapy by blocking focal adhesion kinase. Gynecol. Oncol. 123(2), 432 (2011).
72. Thanapprapasr D. Focal adhesion kinase related gynecologic cancer: a review. Thai J. Obstet. Gynecol. 19, 74-80 (2011).
73. Korets SB, Czok S, Blank SV, Curtin JP, Schneider RJ. Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin. Cancer Res. 17(24), 7518-7528 (2011).
74. Li T, Yang Y, Li X, Xu C, Meng L. EGFR-and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells. Mol. Cell Biochem. 361(1-2), 19-29 (2012).
75. Diaz-Montes TP, Ji H, Smith Sehdev AE et al. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol. Oncol. 100(1), 139-144 (2006).
76. Konecny GE, Santos L, Winterhoff B et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer 100(1), 89-95 (2009).
77. Odicino FE, Bignotti E, Rossi E et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int. J. Gynecol. Cancer 18(1), 14-21 (2008).
78. Santin AD, Bellone S, Van Stedum S et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104(7), 1391-1397 (2005).
79. Swisher EM, Peiffer-Schneider S, Mutch DG et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 85(1), 119-126 (1999).
80. Sasaki H, Nishii H, Takahashi H et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 53(8), 1906-1910 (1993).
81. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod. Pathol. 15(10), 1032-1037 (2002).
82. Moreno-Bueno G, Hardisson D, Sanchez C et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21(52), 7981-7990 (2002).
83. Scholten AN, Creutzberg CL, van den Broek LJ, Noordijk EM, Smit VT. Nuclear betacatenin is a molecular feature of type I endometrial carcinoma. J. Pathol. 201(3), 460-465 (2003).
84. Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet. Gynecol. 100(6), 1290-1295 (2002).
85. Moreno-Bueno G, Hardisson D, Sarrio D et al. Abnormalities of E-and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J. Pathol. 199(4), 471-478 (2003).
86. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J. Clin. Oncol. 22(7), 1242-1252 (2004).
87. Byron SA, Gartside MG, Wellens CL et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 68(17), 6902-6907 (2008).
88. Pollock PM, Gartside MG, Dejeza LC et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26(50), 7158-7162 (2007).
89. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol. Oncol. 113(3), 370-373 (2009).
90. Mori N, Kyo S, Nakamura M et al. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. Br. J. Cancer 103(6), 889-898 (2010).
91. Konopka B, Janiec-Jankowska A, Kwiatkowska E et al. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum. Pathol. 42(11), 1710-1719 (2011).
92. Miyake T, Yoshino K, Enomoto T et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 261(1), 120-126 (2008).
93. Salvesen HB, Carter SL, Mannelqvist M et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl Acad. Sci. USA 106(12), 4834-4839 (2009).
94. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150(1), 177-185 (1997).
95. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94(9), 2369-2379 (2002).
96. Hayes MP, Wang H, Espinal-Witter R et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res. 12(20 Pt 1), 5932-5935 (2006).
97. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl Cancer Inst. 92(11), 924-930 (2000).
98. Risinger JI, Maxwell GL, Berchuck A, Barrett JC. Promoter hypermethylation as an epigenetic component in type I and type II endometrial cancers. Ann. NY Acad. Sci. 983, 208-212 (2003).
99. Momparler RL. Cancer epigenetics. Oncogene 22(42), 6479-6483 (2003).
100. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62(16), 4535-4539 (2002).
101. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4), 814-824 (2000).
102. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 53(21), 5100-5103 (1993).
103. Faquin WC, Fitzgerald JT, Lin MC, Boynton KA, Muto MG, Mutter GL. Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues. Am. J. Clin. Pathol. 113(4), 576-582 (2000).
104. Zighelboim I, Goodfellow PJ, Gao F et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J. Clin. Oncol. 25(15), 2042-2048 (2007).
105. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2010 Revision, Highlights and Advance Tables. Working Paper No. ESA/P/WP.220 (2011). http://esa.un.org/unpd/wpp/ Documentation/pdf/WPP2010-Highlights.pdf
106. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975-2009-pops09 (2012